A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Completed · Phase 2

Conditions studied: Metastatic Breast Cancer

In brief

The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.

Key facts

Study ID

NCT02102490

Run by

Eli Lilly and Company

People needed

132

Starts

2014-06-10

Expected to finish

2018-10-22

Last updated by the study team

2020-01-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may not qualify if…

• Have either a history of central nervous system (CNS) metastasis or evidence of CNS metastasis on the magnetic resonance image of brain obtained at baseline.
• Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor.
• Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug.
• Have had major surgery within 14 days of the initial dose of study drug.
• Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).

Where it is running

• Northern Arizona Hematology & Oncology Associates — Sedona, Arizona, United States
• HOPE Hematology Oncology Physicians and Extenders — Tucson, Arizona, United States
• Arizona Clinical Research Center — Tucson, Arizona, United States
• Univ of California San Francisco — San Francisco, California, United States
• Sansum Medical Research Foundation — Santa Barbara, California, United States
• Rocky Mountain Cancer Center — Denver, Colorado, United States
• Washington Hospital Center — Washington D.C., District of Columbia, United States
• Florida Cancer Specialists — Fort Myers, Florida, United States
• Advanced Medical Specialties — Miami, Florida, United States
• Florida Cancer Specialists — St. Petersburg, Florida, United States
• Maryland Oncology Hematology, P.A. — Columbia, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Minnesota Oncology/Hematology PA — Minneapolis, Minnesota, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Oncology Hematology Care Inc — Cincinnati, Ohio, United States
• Sarah Cannon Research Institute SCRI — Nashville, Tennessee, United States
• Texas Oncology Cancer Center — Austin, Texas, United States
• Texas Oncology - Bedford — Bedford, Texas, United States
• Presbyterian Hospital Dallas — Dallas, Texas, United States
• Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
• The Center for Cancer and Blood Disorders — Fort Worth, Texas, United States
• Texas Oncology-Memorial City — Houston, Texas, United States
• Texas Oncology-Plano West — Plano, Texas, United States
• Texas Oncology-Sherman — Sherman, Texas, United States
• US Oncology — The Woodlands, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.